The Prism Conformity Trial for Post-Traumatic Stress Disorder in Adolescents
Part of paid clinical trials in New York, New York.
- Sponsor
- GrayMatters Health Ltd.
- Study ID
- NCT06854328
- Status
- Recruiting
Conditions
- Post-Traumatic Stress Disorder in Adolescence
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 21 Years
- Healthy Volunteers
- Not accepted
Interventions
- Prism — DEVICEPrism is using an amygdala-fMRI-guided model for processing EEG signals. The model, termed EEG fMRI pattern (EFP), uses several electrodes EEG-signal to produce a real time amygdala-EFP biomarker signal. GrayMatters' product, Prism, is used to train patients in downregulating the amygdala-derived-EFP biomarker during therapy sessions.
Study Details
Prism is a software as a medical device (SaMD) to be prescribed by clinicians as an adjunct to the standard of care treatment of patients with PTSD. The Prism software device runs on a laptop using an EEG signal input (g).Nautilos PRO (K171669). The primary objective of the study is to extend the use of the FDA cleared Prism for PTSD (K222101) to an adolescent population and to confirm the safety of fifteen (15±3) EEG-NF training sessions using the Prism software in reducing PTSD-related symptoms in adolescents. The study aims to demonstrate the safety profile of Prism, having no device-related serious adverse events (SAEs), consistent with findings in the adult population, throughout the course of Prism treatment in an adolescent population.
Key Dates
- Start date
- Jun 11, 2025
- Status verified
- Jun 2025
- Primary completion
- Aug 1, 2026
- Completion
- Nov 1, 2026
Study Design
- Enrollment
- 45 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Single armEligible participants diagnosed with PTSD will be recruited from the community and from local clinical programs. All subjects will undergo Prism neurofeedback training. Participants will complete 15 neurofeedback training sessions delivered twice per week, on non-consecutive days, over 8 consecutive weeks.
Primary Outcome Measure
Safety reporting [ Time Frame: 1 month ]
Central Contacts
- Jennifer Yarden+972-524897823
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NYU Langone Health | New York | New York | 10016 | General Richard Gallagher, MD (PRINCIPAL_INVESTIGATOR) |